ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
Dow Jones
44.544,66
-0,75%
Euro vs US Dollar
1,03615
0,00%
Bitcoin
102.462,75
0,05%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) News

BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BEAM
DatumZeitQuelleÜberschriftSymbolFirma
30/01/202522h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
30/01/202513h00GlobeNewswire Inc.Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech ConferenceNASDAQ:BEAMBeam Therapeutics Inc
23/01/202513h00GlobeNewswire Inc.Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTRNASDAQ:BEAMBeam Therapeutics Inc
13/01/202513h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
13/01/202513h00GlobeNewswire Inc.Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsNASDAQ:BEAMBeam Therapeutics Inc
06/01/202523h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
06/01/202523h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
03/01/202502h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202401h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202401h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
19/12/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
19/12/202422h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
17/12/202413h00GlobeNewswire Inc.Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
09/12/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
08/12/202419h45GlobeNewswire Inc.Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
07/12/202417h30GlobeNewswire Inc.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
06/12/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
06/12/202413h00GlobeNewswire Inc.Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
04/12/202413h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
04/12/202413h00GlobeNewswire Inc.Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderNASDAQ:BEAMBeam Therapeutics Inc
12/11/202422h01GlobeNewswire Inc.Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
08/11/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
05/11/202415h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
05/11/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202415h00GlobeNewswire Inc.Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
05/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202412h30GlobeNewswire Inc.Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNASDAQ:BEAMBeam Therapeutics Inc
29/10/202411h30GlobeNewswire Inc.Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
21/10/202422h11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BEAMBeam Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BEAM

Kürzlich von Ihnen besucht

NYSE
MRK
Merck
NYSE
DIS
Walt Disney
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AMZN
Amazon.com
TG
TUI1
Tui
COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
NYSE
NKE
Nike
COIN
SOLUSD
Solana
COIN
ADAUSD
Cardano
USOTC
BASFY
BASF (QX)
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
FX
EURUSD
Euro vs US Dollar
NYSE
KO
Coca Cola
COIN
DOGEUSD
Dogecoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten